Conference call scheduled for 4:30 p.m. ET today — Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 — Phase 2 VENTURE-Oral Dosing Trial Evaluating VK2735 in Obesity Underway — Strong Year-End Cash Position of $903 Million Viking Therapeutics, Inc. (“Viking”) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development […]

Delivers Financial and Operational Outperformance in Fiscal Q1; Raises Fiscal 2025 Guidance Ranges for All Metrics Universal Technical Institute, Inc. (NYSE: UTI), a leading workforce solutions provider of transportation, skilled trades and healthcare education programs, reported financial results for the fiscal 2025 first quarter ended December31, 2024. Universal Technical Institute, Inc. operates in tworeportable segments,

Envista Holdings Corporation (NYSE: NVST) today announced results for the quarter ended December 31, 2024. https://mma.prnewswire.com/media/1008600/Envista_Logo.jpg “In Q4 2024, Envista delivered results that were in line with expectations, indicating that our focus on growth, operations, and people is having a positive impact,” said Paul Keel, Envista's CEO. “2024 was a transition year for our company.

Renibus Therapeutics® (“Renibus”), a clinical-stage biopharmaceutical company focusingon the prevention and treatment of cardiac, renal, and metabolic diseases, today announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference, being held February 11-12, 2025, in a virtual format. Jeffrey Keyser, RPh, JD, PhD, President and CEO of Renibus, will present on Wednesday, February 12,

Regal Rexnord Corporation (NYSE: RRX) 4Q Highlights — Diluted EPS Of $0.62; Adjusted Diluted EPS* Of $2.34, Up 2.6% Versus PY — Paid Down $205 Million Of Gross Debt In 4Q. Net Debt/Adjusted EBITDA (Including Synergies)* Of ~3.6x — Cash From Operating Activities Of $213.2 Million; Adjusted Free Cash Flow* Of $185.3 Million, Up 8.4%

Revenues increased 14% for the quarter compared to prior year and 13% year-to-date Positive cash flow from operations for the quarter with $5.2 million of cash at December 31, 2024 Year-to-date net loss decline of $1.1 million BOULDER, CO / ACCESS Newswire / February 5, 2025 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader

(NasdaqGM:RANI), – Oral semaglutide administered via the RaniPill(R) HC (RT-116) demonstrated comparable bioavailability, pharmacokinetics and weight loss to subcutaneous administration – – RT-116 was well tolerated with no serious adverse events – – Data adds to growing body of evidence of the RaniPill(R) platform's potential to enable oral delivery of multiple obesity treatments – –

(NASDAQ:NATR),(TSX:THNC),(NYSE:PBI), LEHI, Utah, Feb. 05, 2025 (GLOBE NEWSWIRE) — Nature's Sunshine Products, Inc. (Nature's Sunshine) (NASDAQ: NATR), a leading manufacturer of high-quality herbal and nutritional supplements, today announced the appointment of Ms. Katie A. May to its board of directors effective January 30, 2025. Nature's Sunshine's board will now consist of ten directors with nine

(NASDAQ:TERN), FOSTER CITY, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity, today announced that members of senior management will be participating in a presentation at the Oppenheimer 35th

(NYSE:RAMP), Revenue up 12% Year-Over-Year Fourth Consecutive Quarter of Double-Digit Revenue Growth Fiscal YTD Operating Cash Flow up 17% Year-Over-Year SAN FRANCISCO, Feb. 05, 2025 (GLOBE NEWSWIRE) — LiveRamp(R) (NYSE: RAMP), the leading data collaboration platform, today announced its financial results for the fiscal 2025 third quarter ended December 31, 2024. Q3 Financial Highlights1 Total